secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-06-11T11:12:53+00:00
Accession:  0001193125-26-266688
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio Announces Positive Initial Phase 1b Data for Budoprutug in Immune Thrombocytopenia
--------------------------------------------------------------------------------

- Phase 1b enrolled 15 patients at 250 mg (n=6) and 500 mg (n=9) doses, median follow-up 38 and 12 weeks respectively.
- Budoprutug was well tolerated with no serious adverse events, no discontinuations, and all AEs Grade 1-2.
- In 250 mg cohort, B-cells depleted by >90% at Week 4; mean platelet count increased by 111,000/µL at Week 24.
- Four of six patients achieved durable platelet responses; two had platelet levels ≥100x10^3/µL for over 24 weeks.
- Of four patients previously treated with rituximab, three responded to budoprutug, two with durable/complete responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/0001193125-26-266688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/d63753d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-266688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer